Login to Your Account

'Quest' for Companion Diagnostics

Personalized Approach Renews Tysabri's Potential in MS Space

By Jennifer Boggs
Managing Editor

Tuesday, January 24, 2012
Other drug development firms could learn a lesson from Biogen Idec Inc. and Elan Corp. plc, which turned once-troubled multiple sclerosis (MS) drug Tysabri (natalizumab) into a potential multi-billion-dollar-a-year product by adopting a personalized medicine approach.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription